Completed PHASE2 INTERVENTIONAL 1-arm NCT04942730

Benadamustine, Fludarabine and Busulfan Conditioning in Recipients of Haploidentical Stem Cell Transplantation (FluBuBe) (FluBuBe)

Sponsor: St. Petersburg State Pavlov Medical University

Conditions Biphenotypic Acute Leukemia Leukemia, Acute Lymphoblastic Lymphoblastic Lymphoma Myelodysplastic Syndromes Myeloid Leukemia, Acute Myeloproliferative Neoplasm

Interventions Bendamustine Hydrochloride Busulfan Cyclophosphamide Fludarabine Mycophenolate Mofetil Tacrolimus 5Mg Cap

Updated 6 times since 2021 Last updated: May 6, 2024 Started: Jan 21, 2021 Primary completion: Apr 30, 2024 Completion: Apr 30, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04942730, this PHASE2 trial focuses on Biphenotypic Acute Leukemia and Leukemia, Acute Lymphoblastic and remains completed. Sponsored by St. Petersburg State Pavlov Medical University, it has been updated 6 times since 2021, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jun 2024 — Jul 2024 [monthly]

Completed PHASE2

Status: Recruiting → Completed
Sep 2022 — Jun 2024 [monthly]

Recruiting PHASE2

▶ Show 1 earlier version

Sep 2021 — Sep 2022 [monthly]

Recruiting PHASE2

First recorded

Jan 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

St. Petersburg State Pavlov Medical University

Data source: St. Petersburg State Pavlov Medical University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Saint Petersburg, Russia